Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1956 1
1961 1
1962 3
1963 4
1964 5
1965 13
1966 6
1967 10
1968 5
1969 13
1970 9
1971 13
1972 5
1973 13
1974 8
1975 18
1976 9
1977 16
1978 16
1979 13
1980 22
1981 31
1982 22
1983 22
1984 23
1985 27
1986 26
1987 44
1988 42
1989 30
1990 30
1991 42
1992 38
1993 44
1994 41
1995 52
1996 52
1997 76
1998 80
1999 71
2000 94
2001 72
2002 112
2003 86
2004 83
2005 106
2006 95
2007 108
2008 130
2009 128
2010 121
2011 131
2012 144
2013 161
2014 125
2015 139
2016 127
2017 136
2018 123
2019 154
2020 184
2021 171
2022 160
2023 158
2024 176
2025 126

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,951 results

Results by year

Filters applied: . Clear all
Page 1
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.
Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, Nishida N, Ogawa C, Tomonari T, Nakamura N, Kuroda H, Takebe A, Takeyama Y, Hidaka M, Eguchi S, Chan SL, Kurosaki M, Izumi N. Kudo M, et al. Among authors: nakamura n. Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep. Liver Cancer. 2023. PMID: 37901197 Free PMC article.
Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, Yoshino T. Bando H, et al. Among authors: nakamura n. Clin Cancer Res. 2022 Mar 15;28(6):1136-1146. doi: 10.1158/1078-0432.CCR-21-3213. Clin Cancer Res. 2022. PMID: 35063964 Free PMC article.
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H; PRECISE–IVUS Investigators. Tsujita K, et al. Among authors: nakamura n. J Am Coll Cardiol. 2015 Aug 4;66(5):495-507. doi: 10.1016/j.jacc.2015.05.065. J Am Coll Cardiol. 2015. PMID: 26227186 Free article. Clinical Trial.
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.
Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y, Sakata S, Kamada Y, Nakamoto-Matsubara R, Tran NB, Izutsu K, Sato Y, Ohta Y, Furuta J, Shimizu S, Komeno T, Sato Y, Ito T, Noguchi M, Noguchi E, Sanada M, Chiba K, Tanaka H, Suzukawa K, Nanmoku T, Hasegawa Y, Nureki O, Miyano S, Nakamura N, Takeuchi K, Ogawa S, Chiba S. Sakata-Yanagimoto M, et al. Among authors: nakamura n. Nat Genet. 2014 Feb;46(2):171-5. doi: 10.1038/ng.2872. Epub 2014 Jan 12. Nat Genet. 2014. PMID: 24413737
Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP-STAR study.
Nakajima H, Okada H, Kogure A, Osaka T, Tsutsumi T, Onishi M, Mitsuhashi K, Kitagawa N, Mogami S, Kitamura A, Ishii M, Nakamura N, Kishi A, Eiko S, Hamaguchi M, Fukui M. Nakajima H, et al. Among authors: nakamura n. J Diabetes Investig. 2024 Dec;15(12):1809-1817. doi: 10.1111/jdi.14314. Epub 2024 Sep 18. J Diabetes Investig. 2024. PMID: 39292166 Free PMC article. Clinical Trial.
Genetic profiles and clinical features in subcutaneous panniculitis-like T-cell lymphomas.
Okamura Y, Makishima K, Suehara Y, Suma S, Abe Y, Matsuoka R, Sakamoto T, Hattori K, Yokoyama Y, Kato T, Nanmoku T, Iwasaki T, Nishiyama K, Kato K, Takeuchi Y, Makishima H, Nakamura N, Chiba S, Sakata-Yanagimoto M. Okamura Y, et al. Among authors: nakamura n. Cancer Sci. 2024 Nov;115(11):3788-3794. doi: 10.1111/cas.16345. Epub 2024 Sep 17. Cancer Sci. 2024. PMID: 39288772 Free PMC article.
Orphan GPR116 mediates the insulin sensitizing effects of the hepatokine FNDC4 in adipose tissue.
Georgiadi A, Lopez-Salazar V, Merahbi RE, Karikari RA, Ma X, Mourão A, Klepac K, Bühler L, Alfaro AJ, Kaczmarek I, Linford A, Bosma M, Shilkova O, Ritvos O, Nakamura N, Hirose S, Lassi M, Teperino R, Machado J, Scheideler M, Dietrich A, Geerlof A, Feuchtinger A, Blutke A, Fischer K, Müller TD, Kessler K, Schöneberg T, Thor D, Hornemann S, Kruse M, Nawroth P, Pivovarova-Ramich O, Pfeiffer AFH, Sattler M, Blüher M, Herzig S. Georgiadi A, et al. Among authors: nakamura n. Nat Commun. 2021 May 20;12(1):2999. doi: 10.1038/s41467-021-22579-1. Nat Commun. 2021. PMID: 34016966 Free PMC article.
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution.
Suma S, Suehara Y, Fujisawa M, Abe Y, Hattori K, Makishima K, Sakamoto T, Sawa A, Bando H, Kaji D, Sugio T, Kato K, Akashi K, Matsue K, Carreras J, Nakamura N, Suzuki A, Suzuki Y, Ito K, Shiiba H, Chiba S, Sakata-Yanagimoto M. Suma S, et al. Among authors: nakamura n. Leukemia. 2024 Feb;38(2):340-350. doi: 10.1038/s41375-023-02093-7. Epub 2023 Nov 27. Leukemia. 2024. PMID: 38012392 Free PMC article.
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.
Aoki T, Kudo M, Nishida N, Ueshima K, Tsuchiya K, Tada T, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Kuroda H, Nakamura N, Hiraoka A, Tomonari T, Tani J, Naganuma A, Kakizaki S, Ogawa C, Hatanaka T, Ishikawa T, Kawata K, Takebe A, Matsumoto I, Hidaka M, Kurosaki M, Kumada T, Izumi N. Aoki T, et al. Among authors: nakamura n. J Gastroenterol. 2025 Jun;60(6):738-753. doi: 10.1007/s00535-025-02233-z. Epub 2025 Mar 7. J Gastroenterol. 2025. PMID: 40055288 Free PMC article.
3,951 results